Lisa McShane
Overview
Explore the profile of Lisa McShane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
3165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Platt R, Stallard N, McShane L, Van Calster B, Albert P
Stat Med
. 2025 Jan;
44(1-2):e10273.
PMID: 39775600
No abstract available.
2.
Rahnenfuhrer J, De Bin R, Benner A, Ambrogi F, Lusa L, Boulesteix A, et al.
BMC Med
. 2023 May;
21(1):182.
PMID: 37189125
Background: In high-dimensional data (HDD) settings, the number of variables associated with each observation is very large. Prominent examples of HDD in biomedical research include omics data with a large...
3.
Godsey J, Silvestro A, Barrett J, Bramlett K, Chudova D, Deras I, et al.
Clin Chem
. 2020 Sep;
66(9):1156-1166.
PMID: 32870995
Liquid biopsy, particularly the analysis of circulating tumor DNA (ctDNA), has demonstrated considerable promise for numerous clinical intended uses. Successful validation and commercialization of novel ctDNA tests have the potential...
4.
Palmisano A, Krushkal J, Li M, Fang J, Sonkin D, Wright G, et al.
Methods Mol Biol
. 2019 Sep;
2055:649-678.
PMID: 31502173
In recent years, cancer immunotherapy has emerged as a highly promising approach to treat patients with cancer, as the patient's own immune system is harnessed to attack cancer cells. However,...
5.
Rimsza L, Fedoriw Y, Staudt L, Melnick A, Gascoyne R, Crump M, et al.
J Natl Cancer Inst
. 2016 Dec;
108(12).
PMID: 27986882
Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of...
6.
Lerner S, Bajorin D, Dinney C, Efstathiou J, Groshen S, Hahn N, et al.
Bladder Cancer
. 2016 Jul;
2(2):165-202.
PMID: 27376138
The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and...
7.
Takebe N, McShane L, Conley B
Nat Rev Clin Oncol
. 2015 Feb;
12(3):132-4.
PMID: 25687910
No abstract available.
8.
Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch J, et al.
Am Soc Clin Oncol Educ Book
. 2014 May;
:71-6.
PMID: 24857062
The promise of precision medicine will only be fully realized if the research community can adapt its clinical trials methodology to study molecularly characterized tumors instead of the traditional histologic...
9.
Dowsett M, Nielsen T, AHern R, Bartlett J, Coombes R, Cuzick J, et al.
J Natl Cancer Inst
. 2011 Oct;
103(22):1656-64.
PMID: 21960707
Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment of the proportion of cells staining for the nuclear antigen Ki67 has become the most widely used method...
10.
Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S, et al.
Arch Pathol Lab Med
. 2010 Jul;
134(7):e48-72.
PMID: 20586616
Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as...